Table 1.
Several recent cases of immunotherapy-induced Lyell’s syndrome.
| Publication, Year | Age | Sex | Cancer Type | Immunotherapy | Time to Admission for TEN |
|---|---|---|---|---|---|
| [33] 2023 | 60 | Man | HCC | Cadonilimab | 29 and 8 days (2 injections) |
| [34] 2023 | 76 | Man | Lung ADK | Sintilimab | 9, 6, and 3 weeks (3 injections) |
| [35] 2023 | 75 | Man | NSCLC and prostate cancer | Pembrolizumab | 18, 15, 12, 9, 6, and 3 weeks (6 injections) |
| [36] 2023 | 75 | Man | NSCLC | Pembrolizumab | 15 days (1 injection) |
| [37] 2023 | 78 | Man | Cholangio carcinoma |
Sintilimab | 19 days (1 injection) |
| [15] 2022 | 82 | Man | Thymic carcinoma |
Sintilimab | 5 and 1 weeks (2 injections) |
| [38] 2022 | 71 | Man | Bladder cancer |
Enfortumab Vedotin | 12 and 4 days (2 injections) |
| [39] 2022 | 45 | Woman | Gastric cancer |
Nivolumab | 6, 4, and 2 weeks (3 injections) |
| Case 1 | 71 | Man | Urothelial carcinoma | Enfortumab Vedotin | 15 and 7 days (2 injections) |
| Case 2 | 65 | Man | Melanoma | Nivolumab/Ipilumumab | 20 days (1 injection) |